Sustained response off therapy after fostamatinib: A chronic refractory ITP case report

Fostamatinib is a SYK-inhibitor drug recently approved by the FDA and EMA for treating chronic immune thrombocytopenia. This drug induces a response in about 40% of patients and has a good toxicity profile. It is known that discontinuing thrombopoietin receptor agonists (TRAs) with the maintenance o...

Descripción completa

Detalles Bibliográficos
Autores principales: Auteri, Giuseppe, Biondo, Mattia, Mazzoni, Camilla, Venturi, Marta, Romagnoli, Andrea Davide, Paglia, Simona, Cavo, Michele, Vianelli, Nicola, Palandri, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946849/
https://www.ncbi.nlm.nih.gov/pubmed/36846652
http://dx.doi.org/10.1016/j.heliyon.2023.e13462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946849/
https://www.ncbi.nlm.nih.gov/pubmed/36846652
http://dx.doi.org/10.1016/j.heliyon.2023.e13462

Ejemplares similares